ASSOCIATOIN OF CHINESE AMERICANS IN CANCER RESEARCH

Association of Chinese Americans in Cancer Research Newsletter

Volume 2, Issue 8 February 2022

Inside this issue:

President's welcome message

Dear fellow ACACR members and friends,

I trust that you and your families are having a wonderful New Year and faring well with the recent Omicron surge. I would like to take this opportunity to highlight several recent and future events of ACACR.

In the past summer, we have successfully held the ACACR Virtual Annual Meeting Seminar Series for the second time, featuring presentations by 26 outstanding speakers and 2 Panel Discussion meetings. The events were very well received with 100-150 in attendance almost every week. The feedback was overwhelmingly positive. On behalf of the organizing committee, we would like to thank all speakers, attendees, and other involved parties. It would not be possible without your tremendous help and support.

ACACR has continued to work with other organizations to support the community of Chinese American scientists. The open letter "Stop hate crimes and racism" signed by ACACR and 34 other organizations has been published in Nature, Science, and other journals. ACACR has recently endorsed Dr. David Ho to run for the Director of the National Institutes of Health (NIH).

Please also join me to congratulate several members: Dr. Li Ma for receiving a Sue Eccles Award in Cancer Metastasis Research, Dr. Erxi Wu for an editorial board membership of Medicinal Research Reviews, and Dr. Yong Li for being elected as a Fellow of the American Association for the Advancement of Science (AAAS). We very extremely proud of their remarkable achievements.

We all hope things will go back to normal and we can finally meet in person again. The ACACR has planned a scientific meeting concurrent with the AACR annual meeting in New Orleans, LA. This event is scheduled to take place from 2:00-10:00 pm, Saturday, April 09, 2022. We plan to invite several prominent scientists to speak on exciting topics, followed by a social gathering and reception. The venue has already been booked despite the possibility of virtual hosting due to the pandemic. The ACACR will keep you updated as we are approaching to the meeting date. On behalf of the organizing committee, I warmly welcome you to join us and look forward to having a lot of fun there!

Wish you and your families a prosperous and wonderful year of tiger!

Lin Zhang, PhD
President, ACACR
Professor
UMPC Hillman Cancer Center
Department of Pharmacology & Chemical Biology,
University of Pittsburgh School of Medicine
Pittsburgh, PA 15213-1863
Phone: 412-623-1009; Fax: 412-623-7778
Email: zhanglx@upmc.edu

Preliminary Program of the 2022 ACACR Annual Meeting (see also online)

When: 2:00 – 10:00 pm, Saturday, April 09, 2022

Where: TBD, New Orleans, LA

Tentative agenda

3:00 – 3:05 Welcome and introduction

3:05 – 3:15 ACACR Presidential Address

3:15 –3:45 Keynote Address: Hua Lu, PhD

3:45 –4:15 Keynote Address: TBD

4:15 –4:45 Keynote Address: TBD

4:45 – 5:05 ACACR Cooperate member representatives

5:05 – 5:15 AACR representative

5:15 – 5:20 ACACR annual financial report

5:20 – 5:25 Update on ACACR Publication/newsletters: Drs. Zhenghe Wang and Lanjing Zhang

5:25 – 5:30 Closing Remarks/Future plans

5:30 – 6:00 Networking/Social

6:00 – 8:00 Dinner/Social

Organizing committee:

Gensheng Feng, PhD; Tongchuan He, MD, PhD; Lin Zhang, PhD; Shi-Yuan Cheng, PhD; Zhenkun Lou, PhD; Gloria Su, PhD; Yong Li, PhD; Erxi Wu, PhD

Asian American Academy of Science and Engineering

AAASE

Inaugural Distinguished Lecture

The Contributions of Asian Americans in U.S. Science and Engineering

Speaker

Professor
Steven Chu

- Stanford University
- Nobel Laureate
- 12th U.S. Secretary of Energy

Moderator

Dr. Ajay Mehta

- Vice President of Engineering Technology
- Shell

- What's our role in Science and Engineering in the U.S. and the world?
- What have we contributed and achieved?
- What challenges are we facing? What's the road ahead?

AAASE Website:
www.aaase.org

02/25/22
Friday
8:30 PM ET

To Register
Press or Scan
the QR Code

Statement on Amy Wax's Anti-Asian Comments

CUAFA
Columbia University Asian Faculty Association

To: President Gutmann, Interim Provost Winkelstein, and Dean Ruger
From: Case Western Reserve University Asian Faculty Association
Columbia University Asian Faculty Association
Association of Chinese Professor at Tulane University

Date: January 28, 2022

Re: Amy Wax's Anti-Asian Comments

We, as faculty members at universities across the country, were disappointed and appalled at the University of Pennsylvania faculty Amy Wax's anti-Asian comments that she made publicly in her December 20 interview with Glenn Loury. Not only did Amy Wax disrespectfully ignore the indispensable contributions that Asian Americans have made to the U.S. society, but her ignorant and offensive comments help spread racism and xenophobia against Asian Americans, in particular at a time when hatred and violence targeted the Asian American community have increased. The impact of such anti-Asian hate has been deeply felt on U.S. campuses as some of our Asian American students have shared with us feelings of alienation, vulnerability, and fear.

Speech such as Amy Wax's that further spreads discrimination and hatred is an abuse of freedom of expression. To our knowledge, Amy Wax has repeatedly instigated racist sentiment towards multiple racial groups over the past few years. Such behaviors should be held accountable. Failure to do so will leave racist comments a safe harbor within the university and will only embolden discrimination and antagonism against the racial and ethnic minorities community.

The University of Pennsylvania is committed to "achieving eminence through diversity", as is revealed in President Gutmann's statement on diversity (https://diversity.upenn.edu/diversity-at-penn) . We respectfully urge you to make a meaningful response by condemning Amy Wax's racist comments from the highest level of the university administration and take appropriate disciplinary actions to demonstrate that the University of Pennsylvania lives by its values.

Sincerely,

1. Zhenghe John Wang, President of Asian Faculty Association
Professor, Department of Genetics and Genome Sciences, Case Western Reserve University (CWRU)
2. Youwei Zhang, Associate Professor, Department of Pharmacology, CWRU
3. Wen-Cheng Xiong, Professor, Department of Neurosciences, CWRU

4. Longhua Zhao, Associate Professor, Department of Mathematics, Applied Mathematics and Statistics, CWRU
5. Harihara Baskaran, Professor, Department of Chemical and Biomolecular Engineering, CWRU
6. Masaru Miyagi, Associate Professor, Department of Pharmacology, CWRU
7. Lin Mei, Professor and Chair, Department of Neurosciences, CWRU
8. Xin Yu, Professor, Department of Biomedical Engineering, Radiology, Physiology and Biophysics, CWRU
9. Bingcheng Wang, Professor, Department of Medicine, CWRU
10. Ge Jin, PhD, Professor, Department of Biological Sciences Case Western Reserve University School of Dental Medicine, CWRU
11. Rong Xu, PhD, Professor and Director, Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Dental Medicine
12. Xiongwei Zhu, Professor, Department of Pathology, CWRU
13. Pingfu Fu, Professor of Biostatistics, Department of Population and Quantitative Health Sciences, CWRU
14. Hao Feng, Assistant Professor, Department of Population and Quantitative Health Sciences, CWRU
15. Lihong Shi, Associate Professor, Department of Anthropology, CWRU
16. Peter Yang, Associate Professor, Department of Modern Languages and Literatures, CWRU
17. Paul Park, Associate Professor, Department of Ophthalmology and Visual Sciences, CWRU
18. Raymond Shih Ray Ku, Professor of Law, CWRU
19. Chengfeng Yang, Professor of Medicine, CWRU
20. Wenquan Zou, Professor, Departments of Pathology and Neurology, CWRU
21. Xuan Gao, Professor, Department of Physics, CWRU
22. Sichun Yang, Associate Professor of Nutrition, School of Medicine, CWRU
23. Weihong Guo, Professor and Chair, Department of Mathematics, Applied Mathematics and Statistics, CWRU
24. Man Sun Sy, Professor of Pathology, School of Medicine, CWRU
25. Yang Liu, Assistant Professor, Genetics and Genome Sciences, School of Medicine, CWRU
26. Xiong (Bill) Yu, Professor, Department of Civil and Environmental Engineering, CWRU
27. Amy Zhang, PhD, Associate Professor of Nursing, FPB School of Nursing, CWRU
28. Hua Lou, PhD, Associate Professor, Genetics and Genome Sciences, School of Medicine, CWRU
29. Timothy Chan, Professor and Director, Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic
30. Xiaofeng Zhu, Professor, Department of Population and Quantitative Health Science, Case Western Reserve University
31. Tsan Sam Xiao, Associate Professor, Department of Pathology, Case Western Reserve University
32. Jonathan Y. Tan, The Archbishop Paul J. Hallinan Professor of Catholic Studies, Department of Religious Studies, Case Western Reserve University
33. Hung-Ying Kao, Professor, Department of Biochemistry, Case Western Reserve University
34. Fulai Jin, Assistant Professor, Department of Genetics and Genome Sciences, School of medicine, CWRU
35. Zheng-Rong Lu, M. Frank Rudy and Margaret Domiter Rudy Professor of Biomedical Engineering, CWRU
36. Chris Yuan, Leonard Case Jr. Professor, Department of Mechanical and Aerospace Engineering, CWRU
37. Peijun Chen, MPH, PhD; Department of Psychiatry, CWRU School of Medicine, CWRU
38. Chengfeng Yang, Professor, Department of Medicine, MetroHealth Medical Center, CWRU
39. Jianguo Cheng, Professor of Anesthesiology, Director of the Cleveland Clinic Multidisciplinary Pain Medicine Program, Departments of Pain Management and Neurosciences, Cleveland Clinic
40. Ya-Ting Liao, Assistant Professor, Department of Mechanical and Aerospace Engineering,CWRU
41. Anant Madabhushi, Professor, Department of Biomedical Engineering, CWRU
42. Jing Li, Professor, Department of Computer and Data Sciences, CWRU
43. Xiaonan Han, Associate Professor, Department of Medicine, MetroHealth Medical Center and Case Western Reserve University School of Medicine
44. Yan Li, Assistant professor, Department of Genetics and Genome Sciences, CWRU
45. Ozan Akkus, Professor, Department of Mechanical and Aerospace Engineering, CWRU
46. Qingzhong Kong, Associate Professor, Department of Pathology, School of Medicine, CWRU
47. Yi Zhang, Assistant Professor, Department of Biochemistry, School of Medicine, CWRU

48. Anna Cristina Samia, Associate Professor and Associate Chair, Department of Chemistry, CWRU
49. Angela Ting, Associate Professor, Department of Molecular Medicine, Cleveland Clinic
50. Michiko Watanabe, Professor Emeritus, School of Medicine, Departments of Pediatrics, Genetics, Anatomy, CWRU
51. Chung Chiun Liu, Distinguished University Professor, Department of chemical & Biomolecular Engineering, CWRU
52. Qian Sun, Assistant Professor, Department of Neurosciences, School of Medicine, CWRU
53. Lan Zhou, Professor, Vice Chair for Research, Department of Pathology, School of Medicine, CWRU
54. Kenneth Matreyek, Assistant Professor, Department of Pathology, School of Medicine, CWRU
55. Jennifer Yu, Professor, Dept. of Molecular Medicine, Cleveland Clinic
56. Benjamin D. Li, MD, Professor of Surgery, School of Medicine, Cancer Center Director, MetroHealth System, Immediate Past President, AFA, CWRU
57. Mei Zhang, PhD, Assistant Professor, Department of Biomedical Engineering, SOM, CWRU
58. Guiming Liu, PhD, Associate Professor, Department of Surgery, MHMC, CWRU
59. Yasuhiro Shirai, Professor, Department of Cognitive Science, Case Western Reserve University
60. Chin-Tai Kim, Professor of Philosophy, Department of Philosophy, Case Western Reserve University
61. Yiping Han, President-Elect, Columbia University Asian Faculty Association,
62. Allison Lee, Associate Professor of Anesthesiology at Columbia University Medical Center
63. Erwin de Leon, Chief Diversity Officer and Lecturer, Columbia University School of Professional Studies
64. Stephen Tsang, Professor of Ophthalmology, Pathology & Cell Biology, Columbia University.
65. Wanqing Liu, President of Wayne State University Association for Chinese Faculty and Staff. Associate Professor of Pharmaceutical Sciences & Pharmacology, Wayne State University
66. Ying Wei, Professor of Biostatistics, Columbia University
67. Chang Lee, Associate Professor of Craniofacial Engineering, Columbia University
68. Jianlong Wang, Professor of Medical Sciences (in Medicine), Columbia University
69. Ka Kahe, Professor, Department of Obstetrics and Gynecology, Columbia University
70. Eugenia Lean, Professor, Department of East Asian Languages and Cultures, Columbia University
71. Jennifer Lee, Julian Clarence Levi Professor of Social Sciences, Columbia University72. Wendy K. Chung, Kennedy Family Professor of Pediatrics, Columbia University
73. Jianwen Que, Professor of Medicine, Columbia University
74. Elizabeth Zheng, Assistant Professor of Medicine, Columbia University
75. Bo Shen, MD, The Edelman-Jarislowski Professor of Surgical Sciences and Professor of Medicine, Columbia University
76. Owen Lau, Adjunct Lecturer, Columbia University School of Professional Studies
77. Gloria Su, Professor of Pathology and Cell Biology, Columbia University
78. Songtao Jia, Professor of Biological Sciences, Columbia University
79. Vidhu Thaker, Assistant Professor in Pediatrics, Columbia University
80. Sanat Kumar, Bykhovsky Professor of Chemical Engineering, Columbia University
81. Jianhua Hu, Professor of Biostatistics (in Medicine and in the Herbert Irving Comprehensive Cancer Center), Columbia University
82. Venkat Venkatasubramanian, Samuel Ruben-Peter G. Viele Professor of Engineering, Columbia University, New York
83. Rumela Sen, PhD, School of International and Public Affairs, Columbia University
84. Warren Ng MD, Professor of Psychiatry, Columbia University
85. Lori Yue, Associate Professor, Columbia Business School
86. Kam Leong, Samuel Y. Sheng Professor of Biomedical Engineering, Columbia University
87. Yuanjia Wang, Professor of Biostatistics (in Psychiatry), Mailman School of Public Health, Columbia University
88. Jim Cheng, Director of C.V. Starr East Asian Library, Columbia University
89. Yousin Suh, Charles and Marie Robertson Professor of Reproductive Sciences, Columbia University
90. Chunhua Weng, Professor of Biomedical Informatics, Columbia University
91. Luona Sun MD, Assistant Professor, Department of Surgery, Columbia University
92. Li Qiang, Ph.D., Assistant Professor, Department of Pathology and Cell Biology, Columbia University

93. Ning Qian, Associate Professor, Department of Neuroscience, Columbia University
94. Ruiwei Jiang, Associate Professor, Department of Industrial and Operations Engineering, University of Michigan
95. X. Edward Guo, President, Columbia University Asian Faculty Association, Chair and Stanley Dicker Professor of Biomedical Engineering, Columbia University
96. Sachin Jambawalikar, Chief of Medical Physics, Assistant Professor of Radiology in Biomedical Engg, Columbia University
97. Tian Zheng, Professor and Chair of Statistics, Columbia University
98. Xuebing Wu, Assistant Professor, Department of Medicine, Department of Systems Biology, Columbia University
99. Teeda Pinyavat, Assistant Professor, Department of Anesthesiology, Columbia University
100. Lisa K. Son, Professor, Department of Psychology, Barnard College
101. Anupama Rao, Director, Institute for Comparative Literature and Society, Columbia University and Associate Professor, History, Barnard College
102. Richard Carvajal, MD, Associate Professor of Medicine, Director of Experimental Therapeutics and the Melanoma Program, Columbia University
103. Tony J. Wang, MD, Professor, Department of Radiation Oncology, Columbia University
104. Haijun Zhang, MD, Assistant Professor, Department of Anesthesiology, Columbia University
105. Michael T. Yin, MD MS, Associate Professor of Medicine, Columbia University
106. Wei Gu, Ph.D. Professor, Columbia University Medical Center
107. Qiang Du, Professor, Department of Applied Physics and Applied Mathematics, Columbia University
108. Changxi Zheng, Associate Professor, Department of Computer Science, Columbia University
109. Shuang Wang, Professor of Biostatistics, Columbia University
110. Qing Zheng, MD, Associate Professor of Otology Case Western Reserve University
111. CK Qu, MD, PhD, Professor of Pediatrics, Emory University
112. Lydia Liu, Wun Tsun Tam Professor in the Humanities, Columbia University
113. Huiping Liu, MD, PhD, Associate Professor of Pharmacology, Northwestern University
114. Yiping He, PhD, Associate professor of Pathology, Duke University
115. Erxi Wu, PhD, Associate Professor, Texas A&M University Health Science Center
116. Jian Yang, PhD, Professor, Department of Biological Sciences, Columbia University
117. Hua Lu, MD/PhD, Professor, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine.
118. YiPing Chen, PhD, Professor and Chair, Department of Cell and Molecular Biology, Tulane University.
119. Shi-Yuan Cheng, PhD, Professor, Department of Neurology Northwestern University
120. Hua Guo, MD, MS, Assistant professor, Department of pathology and cell biology, Columbia University
121. Sankar Ghosh, Ph.D. Professor, Department of Microbiology & Immunology, Columbia University
122. Merlin Chowkwanyun, MPH, PhD, Donald Gemson Assistant Professor of Sociomedical Sciences, Columbia University
123. Pearl Lim, MD FACOG MHA, Assistant Professor of Dept of Ob/Gyn, Columbia University
124. Junran Zhang, MD/PhD, Department of Radiation Oncology, Ohio State University.
125. Zhenkun Lou, Ph.D. Department of Pharmacology, Mayo Clinic
126. Changcheng Zhu, MD, PhD.Associate Professor, Dept of Pathology, Albert Einstein College of Medicine
127. Annie S. Li, MD, Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine
128. Shiu-Lin Tsai, MD, Associate Professor, Department of Emergency Medicine, Columbia University Medical Center.
129. William Tse, MD, MBA, Professor of Medicine, Department of Medicine, Case Western Reserve University School of Medicine
130. Pamela Flores-Sanchez, MD, Assistant Professor, Department of Emergency Medicine, Columbia University Medical Center
131. Mushui Dai, MD, PhD, Professor, Department of Molecular and Medical Genetics, Oregon Health and Science University
132. Jahar Bhattacharya, MD, DPhil, Professor, Department of Medicine, Columbia University
133. Chuanyong Lu, MD, Assistant Professor, Montefiore Medical Center

134. Kui Ren, Professor of Applied Mathematics, Columbia University
135. Lorraine Ng, MD, Associate Professor, Department of Emergency Medicine, Columbia University
136. Yanhua Wang, MD, Professor, Montefiore Medical Center
137. Gabrielle Phillip, MD, Assistant Professor, Department of Emergency Medicine, Columbia University
138. Michael W. Morris, Chavkin-Chang Chair, Columbia Business School, Columbia University
139. Hong-Wen Deng, Ph. D., Professor, Chief/Director, Tulane Section/Center for Biomedical Informatics and Genomics, Tulane School of Medicine.
140. Jiang He, MD, PhD, Professor and Chair, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine
141. Wu-Min Deng, PhD, Professor, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine.
142. Lu Qi, MD, PhD, HCA Regents Distinguished Chair and Professor, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine
143. Qiuyang Zhang, Ph.D., Assistant Professor, Department of Structural & Cellular Biology, Tulane University School of Medicine.
144. Shengmin Yan, Ph.D., Instructor, Department of Pathology and Laboratory Medicine, Tulane University School of Medicine.
145. Hui Shen, Ph. D., Associate Professor, Associate Director, Tulane Center of Biomedical Informatics and Genomics, Deming Department of Medicine, School of Medicine, Tulane University
146. Changwei Li, MD, PhD, Assistant Professor, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine
147. Fenglei He, PhD. Assistant Professor, Department of Cell and Molecular Biology, Tulane University
148. Hongbing Liu, Ph.D. Assistant Professor, Department of Pediatrics, Tulane University School of Medicine
149. Hua He, Ph.D, Associate Professor, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine,
150. Jun-yuan Ji, PhD, Professor, Department of Biochemistry and Molecular Biology, Tulane University School of Medicine
151. Xiaoying Wang, MD, PhD, Professor, Department of Neurosurgery, Tulane University School of Medicine
152. Kelin Hu, PhD, Research Assistant Professor, Department of River-Coastal Science and Engineering, Tulane University School of Science and Engineering
153. Haitao Zhang, PhD, Associate Professor, Department of Pathology and Laboratory Medicine, Tulane University School of Medicine
154. Xiang Ji, Ph.D., Assistant Professor, Department of Mathematics, Tulane University School of Science and Engineering
155. Tony Hu, Weatherhead Presidential Chair in Biotechnology Innovation, Director of Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine.
156. Xiao-Ming Yin, MD, PhD. Professor, Department of Pathology and Laboratory Medicine, Tulane University School of Medicine.

Summary of the 2021 ACACR Annual Meeting Seminars

Dear ACACR member,

With the hard work of the planning committee, 26 outstanding speakers, such as Shi Yang, Junjie Chen, Xi He, Wei Gu, Yibin Kang, Jean Zhao, Duojia Pan, and Yung-Chi Cheng…., just to name a few here, have covered the topics in almost all cancer research areas. The virtual meetings were successfully held via Zoom on Fridays from 3:00 pm to 4:30 pm EST, from June 11th to September 3rd, 2021. Two speakers presented in each session with 10 min Q & A after each talk. The audience was actively engaged in these interesting lectures. On average, more than 100 people attended these seminars each time on the Fidays.

In response to request of many young PIs, we also had two Panel Discussion Meetings (1st one on 07/01/2021 and the second on 8/30/2021) on Career Development/Promotion and Grantsmanship, with department chairs and highly successful senior PIs as panel members. At least 70 attendees joined each meetings.

On 08/30/2021, we had two expert speakers on NIH Grant Applications. They were Dr. Jianxin Hu, Scientific Review Officer, HBPP Study Section, Center for Scientific Review, NIH and Dr. Betsy Read-Connole, Head – Cancer Etiology Section, Division of Cancer Biology, National Cancer Institute, NIH. Their talks were well received and have drawn more than 100 attendees each time.

We thank all of the invited speakers for supporting the mission of ACACR. We invite all the members and friends in our community to participate this exciting event.

Best regards,

2021 ACACR Virtual Annual Meeting Committee
Gengseng Feng, PhD, Tong-Chuan He, MD, PhD, Lin Zhang, PhD, Shiyuan Cheng, PhD, Zhenkun Lou, PhD, Gloria Su, PhD, Yong Li, PhD, Erxi Wu, PhD

Panel Discussion on Career Development, Promotion, and Tenure



Yibin Kang, PhD
Warner-Lambert/
Parke-Davis Professor
Princeton University

Rong Li, PhD
Professor & Chair
George Washington
University

Hua Lu, MD/PhD
Professor & Chair
Tulane University

Dihua Yu, MD/PhD
Professor & Chair
MDACC

Bios of Some Speakers for the 2021 Annual Meeting Seminars

Dr. Shi-Yuan Cheng is currently a tenured Professor of Neurology at The Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, and the Lurie H. Robert Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL USA. Dr. Cheng was the President of US Chinese Anti-Cancer Association (USCACA) in 2013-2017, a non-profit professional organization that facilitates collaborations among cancer researchers and physicians in US and China. Dr. Cheng was also the funding president of Association of Chinese American in Cancer Research (ACACR). Dr. Cheng received his BS degree in biochemistry from Wuhan University in Wuhan, China in 1982 and his PhD degree in biochemistry from The Ohio State University in Columbus, Ohio, USA in 1992. From 1992 to 1999, Dr. Cheng received his postdoctoral trainings at UCSD and the Ludwig Institute for Cancer Research in La Jolla, California, USA. From 1999 to 2012, Dr. Cheng was appointed as an Assistant then a tenured Associate Professor at University of Pittsburgh Cancer Institute (now Hillman Cancer Center) & Department of Pathology at University of Pittsburgh School of Medicine, Pittsburgh, PA. In 2012, Dr. Cheng joined faculty at Northwestern University as a tenured Professor at the Department of Neurology. Dr. Cheng is a fellow of American Association for the Advancement of Science (AAAS). He was also honored as a Zell Scholar by Zell Family Foundation at Northwestern University. He was also honored as a Kimmel Scholar by the Sidney Kimmel Foundation for Cancer Research, a V Scholar by the V Foundation for Cancer Research and Wang Kuan-Cheng Award for Outstanding Oversea Young Scientist, Chinese Academy of Sciences, China. Dr. Cheng is/was an editorial board member of Neuro-Oncology, Journal of Biological Chemistry, Journal of Neuro-oncology. Dr. Cheng has published 90 peer-reviewed research articles in top-ranking biomedical journals as first, senior or co-author including Cancer Cell, Nat Cell Biol., Mol. Cell, JCI, Nat Commoms, PNAS, Cell Reports, Cancer Res. and 15 invited review articles and book chapters. Dr. Cheng has been an expert reviewer including several terms of charter members for numerous study sections at NIH, Army Breast Cancer Research Program, Susan G. Komen Foundation, Juvenile Diabetes Research Foundation, Medical Research Council (England), Cancer Research UK, Canada Foundation for Innovation and Fund, National de la Researche, Luxemboug and others. Dr. Cheng's research has been continuously supported by grants from the US NIH, American Cancer Society, The US Amy Breast Cancer Research Program, and other agencies. He currently holds an active NIH R01, a project of NCI Specialized Programs of Research Excellence (SPORE) on Brain Cancer, and sponsors for an NCI K00 postdoctoral awardee. Dr. Cheng is a regular reviewer for >80 peer-review scientific journals. Dr. Cheng's research interests are to study dysregulated oncogenic signaling, non-coding RNAs, RNA splicing, autophagy, and epigenetics in brain gliomas and develop novel therapeutic approaches for treating brain tumors and other

Dr. Xi He received a bachelor's degree in Mechanical Engineering at Huazhong University of Science and Technology in Wuhan, China, and Ph.D. with Dr. Michael G. Rosenfeld at UCSD. He performed postdoctoral training with Dr. Harold Varmus at NCI. Dr. He became an assistant professor at Boston Children's Hospital and Harvard Medical School in 1997 and rose to the rank of professor in 2007. Dr. He was a Pew Scholar in biomedical sciences, Klingenstein Fellow in neuroscience, W. M. Keck Distinguished Young Scholar in medical research, and Leukemia and Lymphoma Society Scholar. Dr. He is a Fellow of American Association for the Advancement of Science (AAAS), and is currently American Cancer Society Harry and Elsa Jiler Endowed Research Professor. Dr. He's lab focuses on understanding the mechanism of Wnt signaling in vertebrate development and human diseases including cancer. He is particularly interested in canonical Wnt/ -catenin signaling and noncanonical Wnt signaling in Xenopus embryonic patterning and neural development. He is also interested in stem cell biology and disease modeling in mice and organoids, and therapeutic targeting of Wnt signaling in cancer and other diseases. Through systematic identifications of critical steps and components of Wnt signaling pathways, Dr. He has made significant contributions to the field of Wnt signaling, including (i) mechanisms of the Wnt receptor complex formation and its signal transduction across the plasma membrane; (ii) mechanisms by which Wnt signaling mediator -catenin is degraded and stabilized by the Wnt receptors; (iii) mechanisms by which Wnt signaling is regulated by extracellular Wnt antagonists and agonists during vertebrate development; and (iv) non-canonical Wnt signaling mechanism and involvement in vertebrate gastrulation movements; (v) deregulation of Wnt signaling in diseases including cancer. Dr. He's research has been influential and highly cited in the primary literature and textbooks on developmental and cancer biology. Dr. He has served on numerous review and advisory boards in academia in the US, Canada, EU, UK, and China, and in biopharmaceutical industry in the US and EU.

Dr. Wenshe Ray Liu received his Ph.D. degree in chemistry from UC Davis in 2005 and then finished a two-year postdoc training in Scripps Research Institute. He started his independent research career in 2007 at Texas A&M University as Assistant Professor and quickly ascended to Associate Professor in 2013 and Full Professor in 2016. He was the inaugural holder of the Emile & Marta Schweikert Professorship in Chemistry from 2014 to 2018, the current holder of Gradipore Chair in Chemistry, and a TAMU Presidential Impact Fellow since 2018. Dr. Liu was a previous director of the TAMU Chemistry Mass Spectrometry Laboratory. He is currently chairing the Chemical Biology division in the Chemistry Department and the director of the Texas A&M Drug Discovery Laboratory. Dr. Liu is leading a large research group with about 20 postdocs and graduate students. The focus of his research is to invent novel techniques for identifying therapeutics for cancer and other diseases. Grants for his research have amounted to more than $5,000,000 from NIH, NSF, CPRIT, Welch Foundation, etc. So far he has published about 70 highly visible research articles. For his significant research contributions, he has received multiple awards including an NSF CAREER Award, a CAPA Distinguished Faculty Award, and the Texas A&M Presidential Impact Fellow. When the current COVID-19 pandemic just unfolded in China, Dr. Liu quickly put his research group into action to find cures. His group was the first to point out that remdesivir is a viable treatment option for COVID-19 and has been actively identifying both small molecule and peptide inhibitors that can prevent COVID-19 virus replication and neutralize it for entry into human cell hosts.

Dr. Yong Wan obtained his PhD from Cornell University in 1997 and had his postdoctoral training with Dr. Marc Kirschner at Harvard University from 1997-2002. Yong was independent in 2003 as an assistant professor at the Department of Cell Biology and Hillman Cancer Center at University of Pittsburgh. There, he was promoted as Associate Professor and Full-Professor. Yong was recruited by Lurie Cancer Center and Department of OBGYN at Feinberg School of Medicine Northwestern University in 2017.

Yong's lab studies the molecular mechanisms of breast carcinogenesis, and to identify novel targets for therapeutic development. Particularly, his laboratory seeks to address how defects in the ubiquitin-proteasome system and other posttranslational modifiers such as protein methyltransferase, poly (ADP-ribose) polymerase and glycosyltransferase would result in genomic instability, deregulated tumor immune checkpoint function, and aberrant signaling that predispose otherwise normal cells to become cancerous tumor cells or promote cancer progression and metastasis. He will talk about the impact of interplay between glycosylation and ubiquitylation in regulating B7-H4, an immune checkpoint protein, in breast carcinogenesis and breast cancer therapy.



Dr. Qin Yan is an Associate Professor and Director of Epigenetics Program in the Department of Pathology at Yale Medical School. He co-leads the Breast Cancer Team Science Group (BrCaTSG) at the Yale Comprehensive Cancer Center. He is also a member of Yale Center for Immuno-Oncology and Yale Stem Cell Center. He directs a research laboratory to elucidate the roles of epigenetic mechanisms that drive tumor initiation and progression and to translate the findings into the clinic, focusing on cancer metastasis, tumor immunoevasion, drug resistance and development of epigenetic therapies. His laboratory has made significant contributions to the understanding of the KDM5/JARID1 histone demethylases and epigenetic regulation of antitumor immunity. Dr. Yan received his B.S. degree from the University of Science and Technology of China. After his Ph.D. training on regulation of transcription and ubiquitination with Drs. Joan and Ronald Conaway at the Oklahoma Medical Research Foundation and Stowers Institute for Medical Research, he completed his postdoctoral training on cancer biology with Nobel laureate Dr. William Kaelin at the Dana-Farber Cancer Institute and Harvard Medical School. He has received a number of awards including Era of Hope Scholar Award from DoD Breast Cancer Research Program, Stewart Scholar Award and V Scholar Award.

Members' Research Highlights

Dr. **Taosheng Chen** at St. Jude Children's Hospital discovered a unique conformation of a surface loop of CYP3A5 enabling the selective binding of potential inhibitors, which can be exploited for the development of specific inhibitors of CYP3A5. This work was published and featured as a cover article in the high-impact journal JACS. https://pubs.acs.org/doi/10.1021/jacs.1c07066.

Dr. **Xiaohong Li** at the University of Toledo discovered enzalutamide-induced downregulation of TGFBR2 through PTH1R-mediated endocytosis as a novel resistant mechanism to the drug in prostate cancer. This work was published in a high-impact journal Cancer Letters. https://www.sciencedirect.com/science/article/pii/S0304383521005589

Dr. **Huiping Liu** at Northwestern University made several seminal discoveries on circulating tumor cell clusters in promoting cancer metastasis that were published in high-impact journals Nature communications, Theranostics, and Cancers, respectively: https://www.nature.com/articles/s41467-021-25189-z; https://www.thno.org/v11p6632.htm; https://www.mdpi.com/2072-6694/13/11/2550; Moreover, she found that circulating ACE2-expressing exosomes prevents COVID infection that is in press in Nature communications.

Dr. **Zhenkun Lou** at Mayo Clinic continued his very productive year and published several high-impact papers in the second half of 2021. First, his group discovered c-MET amplification renders lung cancers resistant to immune checkpoint therapy through downregulation of STING and inhibition of CD8 T cell infiltration. https://cancerdiscovery.aacrjournals.org/content/11/11/2726.long; Second, he discovered that E3 ubiquitin ligase RNF19A promotes BARD1 ubiquitination and nuclear export of BRCA1 and BARD1. Moreover, breast cancers expressing high levels of RNF19A are sensitive to PARP inhibitors. https://www.nature.com/articles/s41467-021-27048-3. Third, in collaboration with Dr. **Jian Yuan,** he found that a new 3' overhang processing endonuclease called ASTE1 inhibits homologous and promotes non-homologous end joining, which is important for maintaining class switching, genomic instability, and lifespan. https://pubmed.ncbi.nlm.nih.gov/34354233/

Dr**. Hua Lu** at Tulane University discovered valosin-containing protein (VCP) as a novel regulator of p53-R273H mutant protein stability, which was published in a high-impact journal Cancer Research. https://pubmed.ncbi.nlm.nih.gov/34099490/; Moreover, he developed a novel nanoparticle to enhance the therapeutic effect of p53 activator Inauhzin. https://pubmed.ncbi.nlm.nih.gov/34093867/; In collaboration with Dr. Xiang Zhou, he made several novel players in the p53 and AKT pathways. https://pubmed.ncbi.nlm.nih.gov/34266953/; https://pubmed.ncbi.nlm.nih.gov/34459128/; https://pubmed.ncbi.nlm.nih.gov/34621748/; https://pubmed.ncbi.nlm.nih.gov/34621748/.

Dr. **Li Ma** at MD Anderson Cancer Center recently published three Nature Communications papers on a variety of topics. First, she discovered a non-canonical function of DGCR8 in DSB repair signaling and tumor radioresistance. https://www.nature.com/articles/s41467-021-24298-z; Second, she found that that glucocorticoid receptor acts as a transcriptional activator of PD-L1 and a transcriptional repressor of MHC-I in pancreatic cancer cells, thereby modulating the infiltration and activity of cytotoxic T cells. https://www.nature.com/articles/s41467-021-27349-7; Third, she discovered a targetable LIFR—NF-κB—LCN2 axis that controls liver tumorigenesis and vulnerability to ferroptosis. https://www.nature.com/articles/s41467-021-27452-9

Members' Research Highlights (Cont'd)

Dr. **Gloria Su** at Columbia University discovered that loss of the WT KRAS allele promotes pancreatic cancer progression via activation of YAP1 and is associated with poor prognosis in PDAC patients. https://pubmed.ncbi.nlm.nih.gov/34663879/. This provocative finding was featured by the NCI Division of Cancer Research https://twitter.com/NCICancerBio/status/1458049997707096066?s=20

Dr. **Erxi Wu** at Baylor Scott and White Health, in collaboration with Drs. Xiaoxiao Hu and Weihong Tan, developed a novel DNA aptamer S11e that inhibits fibrosarcoma through biding to Diablo/SMAC protein in mitochondria. https://doi.org/10.1016/j.bioactmat.2021.10.011; He reviewed Salinomycin as a potent anticancer stem cell agent (https://doi.org/10.1002/med.21870).

Dr. **Lanjing Zhang** at Rutgers University and Penn Medicine Princeton Medical Center reported interesting and also concerning trends in treatments for prostate cancer in the United States, 2010-2015 https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8167696/. He successfully launched a special section for the Arch Pathol Lab Med on emerging topics in anatomic pathology (https://meridian.allenpress.com/aplm/article/145/6/657/465662/Launch-of-the-Emerging-Topics-in-Anatomic). With help from members of Chinese American Pathologists Association and Princeton Pathology conference speakers, he also jointly completed two special sections for the same journal (https://meridian.allenpress.com/aplm/article/146/1/38/476146/Frontiers-in-Bone-Soft-Tissue-and-Hematologic and https://meridian.allenpress.com/aplm/article/145/11/1355/472419/Updates-and-Diagnostic-Challenges-in-Surgical

Scan the QR code on the right
To join the ACACR annual meeting at 2:00 – 10:00 pm, Saturday, April 09, 2022 In New Orleans, LA

SCAN ME

Genes & Diseases

IF=7.103

JCR ® Category	Rank in Category	Quartile in Category
BIOCHEMISTRY & MOLECULAR BIOLOGY	48 of 298	Q1
GENETICS & HEREDITY	19 of 175	Q1

Journal Impact Factor Trend 2020



Journal Relationships 2020



Published bimonthly

Open Access

ISSN: 2352-4820
ISSN: 2352-3042
CN: 50-121/R

In partnership with ACACR

Association of Chinese Americans in Cancer Research

Email: editor@ genesndiseases. com

Homepage: www. journals. elsevier. com/genes-and-diseases

Genes & Diseases
An international journal for molecular and translational medicine

Journal Metrics

CiteScore: 7.5 / 79.5% (2020)
Impact Factor: 7.103 (2020/2021)
Source Normalized Impact per Paper (SNIP): 1.312 (2020)
SCImago Journal Rank (SJR): 1.614 (2020)

Review Speed



Published Quarterly
Open Access
ISSN: 2352-3042

Types of Articles

Full length article, review article, short communication, correspondence, perspective, commentary, views on news, and research watch.

Call for Papers

Email: editor@genesndiseases.com
Home page: https://www.journals.elsevier.com/genes-and-diseases/
Journal page: https://www.sciencedirect.com/journal/genes-and-diseases

In partnership with ACACR

Postdoctoral Position in Liver Cancer Research

Department of Cell Systems & Anatomy
School of Medicine, UT Health San Antonio

A postdoctoral position is available immediately in the laboratory of Dr. LuZhe Sun, Dielmann Chair in Oncology and Professor in the Department of Cell Systems & Anatomy, Long School of Medicine, University of Texas Health Science Center at San Antonio. Applicants with experience in bioinformatics and cancer research and seeking to apply cross-disciplinary research approaches and work with an experienced mentor are encouraged to apply. The successful applicant will investigate the molecular mechanisms driving liver carcinogenesis employing bioinformatics approaches for analyzing various omics data generated from human and mouse samples in the lab, molecular and cell biology techniques and animal models for mechanistic investigation, and drug discovery tests. The position is funded by grants from NIH and Clayton Foundation for Research. New graduates with a doctoral degree are particularly welcome to apply. Attractive stipend and fringe benefits will be offered. The University of Texas Health Science Center at San Antonio is a Tier One research institution and the department enjoys a dynamic research program that offers opportunities for multidisciplinary collaborative investigation. San Antonio is a dynamic and multicultural city with a relatively low cost-of-living and an outstanding cultural and educational environment. Please email your CV to SUNL@UTHSCSA.EDU.

All postdoctoral positions are designated as security sensitive positions. UT Health San Antonio is an Equal Employment Opportunity/Affirmative Action Employer.

Scientist, St. Jude Children's Research Hospital

The High Throughput Bioscience (HTB) Center at St. Jude under Director and St. Jude Faculty Member Dr. Taosheng Chen, seeks a senior cell and molecular biologist/chemical biologist to design and implement a variety of cell-based phenotypic screens, ranging from -scale automated cytotoxicity screens, medium-scale genetic loss-of-function siRNA screens, to focused high -content imaging-based screens. The ideal candidate is familiar with high throughput screening and associated data analysis and quality control, and capable of developing/utilizing novel bioassays to solve challenging biology problems. The HTS Scientist reports to the Director of HTB Center and is expected to independently lead and implement collaborative projects; present or publish research results; and assist the Center Director in managing the daily operation of the Center. The HTB Center consists of those with advanced training in biology, chemistry, and engineering who work together on target identification and validation, assay development, laboratory automation, high-throughput and high -content screening (up to 600K small molecules and genome-scale siRNAs), large-scale data processing, and management of scientific collaborations.

PhD in biological sciences with relevant postdoctoral training preferred. Experience with assay development and high-throughput screening is required. Experience in automation, data management, high-content screening and RNAi technology, and a strong publication record are a plus.

Please direct your questions, cover letter, and current CV to Dr. Taosheng Chen (taosheng.chen@stjude.org).

Contact
Taosheng Chen, PhD
Member, Department of Chemical Biology and Therapeutics
Director, High Throughput Bioscience Center
St. Jude Children's Research Hospital
Memphis, TN, 38105-3678, USA
Taosheng Chen: https://www.stjude.org/chen
Chen Lab: https://www.stjude.org/research/labs/chen-lab-taosheng.html
HTB Center: https://www.stjude.org/research/departments/chemical-biology-therapeutics/high-throughput-biosciences.html

Postdoctoral Position in Mammary Stem Cell and Cancer Research

Department of Cell Systems & Anatomy
School of Medicine, UT Health San Antonio

A postdoctoral position is available immediately in the laboratory of Dr. LuZhe Sun, Dielmann Chair in Oncology and Professor of the Department of Cell Systems & Anatomy, Long School of Medicine, University of Texas Health Science Center at San Antonio. Applicants with experience in cancer or stem cell research and seeking to apply cross-disciplinary research approaches and work with an experienced mentor are encouraged to apply. The successful applicant will investigate the molecular mechanisms underlying aberrant aging mammary stem cells. The position is funded by a grant from NIH. New graduates with a doctoral degree are particularly welcome to apply. Attractive stipend and fringe benefits will be offered. The University of Texas Health Science Center at San Antonio is a Tier One research institution and the department enjoys a dynamic research program that offers opportunities for multidisciplinary collaborative investigation. San Antonio is a dynamic and multicultural city with a relatively low cost-of-living and an outstanding cultural and educational environment. Please email your CV to SUNL@UTHSCSA.EDU.

All postdoctoral positions are designated as security sensitive positions. UT Health San Antonio is an Equal Employment Opportunity/Affirmative Action Employer.

Multiple NIH-funded Postdoc/Research Associate positions

Multiple NIH-funded Postdoc/Research Associate positions are available at Division of Cancer Biology, Department of Medicine, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio

Postdoc/Research Associate positions are available to study the mechanism of lung cancer development and progression. The mechanistic studies focus on the roles of epigenetic dysregulations including DNA methylation, histone posttranslational modifications, non-coding RNA (especially long non-coding RNAs) and functional RNA modification (m6A) dysregulations using cell culture and genetically modified mouse models. Highly competitive salaries ($53,000.00 to $63,000.00) and benefits will be offered depending on candidates' qualifications and experience. Excellent candidates with more than 5 years postdoc experience will be appointed as Research Associate (Starting annual salary $72,000 plus competitive benefit). Candidates should have a Ph.D. degree with strong background in following one or more areas including cell/molecular biology, cancer biology, immunology, toxicology or chemistry. Experiences in studying cancer epigenetics, non-coding RNAs especially long non-coding RNAs, functional RNA modifications especially the m6A modification, cancer stem cells, and excellent skills in cloning and manipulating genes, culturing mammalian cells, handling mice, performing surgeries to produce tumors in mice and treating mice with commonly-used drug/toxicant administration approaches would be advantageous. In addition, the qualified candidates are expected to be highly self-motivated with strong interests in learning new knowledge and techniques; have excellent communication and organizational skills and attention to details; be capable of conceptualizing, designing experiments and conducting studies independently as well as cooperatively with other lab members as a team; and have the capability to write manuscripts for quality publications. Interested applicants should submit a recent complete CV, a cover letter of interest describing your research training/experience and future career goal and provide names/contact information of three individuals that can provide academic references upon request to: Dr. Chengfeng Yang: Chengfeng.yang@case.edu

Structural Biologist, St. Jude Children's Research Hospital

We are recruiting a Structural Biologist to join the efforts in structural determination of protein-ligand complexes and contribute structural biology insights into the mechanism of action of novel chemical probes. The Chen Laboratory uses multidisciplinary approaches to study transcriptional regulation by nuclear receptors, including chemical biology approaches to develop chemical modulators, with a goal to understand nuclear receptor-regulated transcription networks and design therapeutic approaches to overcome drug resistance and tumorigenesis in cellular and animal models. The structural biology efforts are expected to synergize with our chemical biology efforts and enable completion of impactful projects (Nat Commun 8:741, 2017; J Am Chem Soc 143:18467, 2021). The Chen Laboratory provides a unique research environment: in addition to basic research, lab members will learn and gain experience in small molecule drug discovery from target validation, chemical probe discovery and optimization to preclinical mechanistic studies. The Senior or Lead Researcher will work in a collaborative and multidisciplinary environment by collaborating with biologists, chemists, and technologists

The successful candidate will have proved experience in expression construct design, molecular cloning, protein expression and purification, optimization of crystallization conditions, crystallization and structural determination of protein-ligand complexes using X-ray crystallography.

Experience in the following areas is a plus: purification and crystallization of nuclear receptors; synchrotron data collection; biophysical assays; in silico modeling of protein-ligand interactions; preparation of manuscripts; along with a strong publication record.

Please direct your inquiries and current CV to Dr. Taosheng Chen (taosheng.chen@stjude.org)

Education
PhD in structural biology is essential, and relevant postdoctoral training is preferred.

Contact
Taosheng Chen, PhD
Member (Professor), Department of Chemical Biology and Therapeutics
Director, High Throughput Bioscience Center
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-2794
USA
Taosheng Chen: https://www.stjude.org/chen
Chen Lab: https://www.stjude.org/research/labs/chen-lab-taosheng.html
HTB Center: https://www.stjude.org/research/departments/chemical-biology-therapeutics/high-throughput-biosciences.html

Postdoctoral Research Associate, St. Jude Children's Research Hospital

The Chen Lab studies the transcriptional regulation of nuclear receptors and fusion oncoproteins by using multidisciplinary approaches, while members of the High Throughput Bioscience (HTB) Center (directed by Dr. Chen) work together on target validation, assay development, and compound screening. We investigate signaling pathways and develop chemical probes to modulate transcription, with a goal to understand transcriptional regulation and design therapeutic approaches to overcome drug resistance and tumorigenesis in cellular and animal models (Nat Commun 8:741, 2017; J Am Chem Soc 143:18467, 2021)

The postdoctoral fellow will work on one or more of the following projects related to either nuclear receptors or fusion oncoproteins:

- Investigate the mechanism of action of chemical probes (including protein degraders)
- Perform structural studies and modeling of compound–protein interactions
- Discover therapeutic targets by data mining followed by experimental validation
- Design assays to discover small molecule modulators of transcription

The Chen Lab provides a unique training environment: in addition to basic research, the postdoctoral fellow will learn and gain experience in small molecule drug discovery from target validation, compound screening to preclinical mechanistic studies. Former Chen Lab postdocs have landed jobs as Assistant Professors in Universities, Senior Scientists in Pharmaceutical Companies, or Staff Scientists at St. Jude.

The successful candidate will work in a collaborative and multidisciplinary environment by collaborating with biologists, chemists, structural biologists, and technologists.

Highly motivated individuals with a strong publication record are encouraged to apply. The successful candidate will have a strong background in either cell/molecular biology or biochemistry/structural biology, experience in studying transcriptional regulation, and interest in investigating compound mechanism-of-action. Candidates must have (or soon receive) a PhD degree.

Contact Information
Taosheng Chen, PhD (Email: taosheng.chen@stjude.org)
Member (Professor), Department of Chemical Biology and Therapeutics
St. Jude Graduate School of Biomedical Sciences
Director, High Throughput Bioscience Center
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-2794
USA
Taosheng Chen: https://www.stjude.org/chen
Chen Lab: https://www.stjude.org/research/labs/chen-lab-taosheng.html
HTB Center: https://www.stjude.org/research/departments/chemical-biology-therapeutics/high-throughput-biosciences.html

Post doctoral and/or Research Associate II position

The James

THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER

The Ohio State University Wexner Medical Center in Columbus, Ohio is the only academic medical center in Central Ohio and ranked as one of "America's Best Hospitals" by U.S. News and World Report for 20 consecutive years! We are committed to comprehensive patient care, high caliber research and innovative medical education for medical students, post-doctoral trainees and professional colleagues. The OSUCCC – James is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic medical center and a free-standing cancer hospital on the campus of one of the nation's largest public universities.

Post doctoral researcher and/or Research Associate II position available in the laboratory of Dr. Junran Zhang with The Ohio State University, Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, https://radiationoncology.osu.edu/research/junranzhang/index.cfm.

Focusing on elucidating the DNA damage response (DDR), and its roles in the maintenance of genomic stability and cancer therapy. Our goal is to provide a molecular basis for providing precise treatment plans for individual patients by studying predictive biomarkers in response to DDR inhibitors, and to identify new targets for cancer treatment by conducting basic and cutting-edge translational scientific research. This position will independently conduct research to identify novel biomarkers to guide the use of DDR inhibitors and seek the optimal combination with targeted therapy, such as inhibitors targeting metabolism and modulating immunotherapy. The candidates are also expected to participate in grants preparation; train staff in molecular biology techniques.

Education/Experience:

A highly motivated candidate is required. Doctoral Degree in cancer/cell/molecular biology, biochemistry or related field required. Expertise in tissue culture, protein biochemistry & molecular biology technique, immunofluorescence microscopy and animal work preferred. Requires successful completion of a background check; qualified candidates may be asked to complete a pre-employment physical including a drug screen. The Ohio State University offers a competitive salary, outstanding benefits, participation in workshops and conferences, high quality Shared Resources, and many opportunities for continued professional development.

Salary Range: $48,000 - $54,000

Applicants need to submit their cover letter and current curriculum vitae to

Junran.zhang@osumc.edu

The Ohio State University offers a competitive salary, outstanding benefits, participation in workshops and conferences, high quality Shared Resources, and many opportunities for continued professional development.

The Ohio State University is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation or identity, national origin, disability status, or protected veteran status.

Postdoctoral Positions at NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE

NIH-funded postdoctoral positions in cancer biology are available in Dr. Shi-Yuan Cheng's laboratory, a highly productive and dynamic research team with an established track record of basic and translational research and mentoring future faculty (http://labs.feinberg.northwestern.edu/cheng/), at Lou & Jean Malnalti Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics at Northwestern University Feinberg School of Medicine in Chicago, IL, USA.

The Cheng Laboratory investigates mechanisms that regulate phenotypes and therapy responses of cancer using patient-derived cancer stem cells (GSCs), PDX, human induced pluripotent stem cell (hiPSC)-derived cancer spheroids, clinical specimens, orthotopic tumor xenografts, and other model systems, and state-of-art techniques of biochemical, molecular, cellular, and bioinformatics. NIH T32 training award opportunities are highly possible at the Lurie Cancer Center for candidates who are US citizen or permanent resident. We are seeking ambitious and outstanding postdocs who are interested in studying the following research areas:
1) Non-coding RNAs (circular RNAs and long non-coding RNAs) in cancer.
2) Multi-omics with emphasis of proteomics and cancer non-response to immunotherapy.
3) Mechanisms of cancer therapy-resistance and targeting development.
4) Other projects in cancer that can be initiated by self-driven, capable, and independent postdocs.

The applicants should have a PhD degree in biochemistry, molecular biology, cancer biology, and well-trained with proficient skills in studying cellular signaling, RNA biology, biochemistry, gene regulation with desired bioinformatic experience. The applicants must have strong publication records with first-author papers in high-impact journals. Fellows are expected to be independent, highly motivated with strong drive to succeed, capable of leading their own research projects and be in charge of all aspects of their project from conception, data generation and analysis to grant submissions and preparation of scientific publications under the guidance of the PI, believe in team science and collaborative, and proficient in English communications.

Selected publications from Cheng Laboratory: Mol Cell, (2021), Nat Cell Biol., (2021), Cancer Cell (2017), Autophagy (2019); Nature Comm., (2016), J. Clin. Invest. (2011, 2014); Proc. Natl. Acad. Sci., USA, (2013).

Please submit a letter of interest, your resume, reprints of relevant publications, and contact information of three references including the PhD mentor. Northwestern University provides NIH-standard annual salary for postdoctoral fellows (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-049.html and an excellent compensation and benefits package https://www.northwestern.edu/hr/benefits/postdoc-benefits.html.

Northwestern University is an Equal Opportunity/Affirmative Action Educator and Employer and invites applications from all qualified individuals. Applications from women and minorities are especially sought.

Contact:
Shi-Yuan Cheng, PhD
Professor, Zell Scholar & AAAS Fellow
The Ken and Ruth Davee Department of Neurology
Lou & Jean Malnati Brain Tumor Institute of Northwestern Medicine
Simpson Querrey Institute for Epigenetics
The Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
303 E. Superior, Lurie 6-119
Chicago, IL 60611, USA
Office: 1-(312)503-3043
E-mail: shiyuan.cheng@northwestern.edu, shiyuancheng@gmail.com
Lab website: http://labs.feinberg.northwestern.edu/cheng/

Postdoctoral Fellowship in Emory Winship Cancer Institute

Emory – Winship Cancer Institute, Atlanta, GA
Application Deadline: Open Until Filled

Job Description
Two Post-Doctoral Research Fellow positions are available immediately under the guidance of Dr. Yong Teng (https://www.researchgate.net/profile/Yong-Teng-2) to study molecular basis underpinning the new links among cancer metastasis, metabolism, and immunity. Using animal models (e.g., orthotopic and PDX models, transgenic mice) along with functional genomics (e.g., CRISPR-Cas9 or shRNA lentivirus), the Post-Doctoral Fellow will work in a NIH-funded laboratory to understand and reverse the molecular mechanisms involved in cancer progression and treatment resistance. The successful applicants will also be dedicated to developing novel anti-cancer strategies and combination therapy to achieve better clinical outcomes.
The position provides a salary higher than internationally competitive rates for postdoctoral positions, in addition to substantial benefits. The successful candidate will benefit from a dynamic and highly collaborative environment and the opportunity to interact with the extended scientific community at Emory Winship Cancer Institute. Members of this team are encouraged to present their research at international meetings.

Requirements:
1. Ideal candidates must have a PhD, have basic experience in standard laboratory techniques for molecular biology/genetics and/or immunology.
2. Preference to applicants who are finishing graduate school or have less than 3 years of post-doctoral experience.
3. Candidates are expected to be able to work independently and possess strong interpersonal communication and analytical skills.
4. Candidates will be motivated, detailed, goal-oriented and possess excellent organizational skills.
5. Prior work experience within the field of cancer biology or translational medicine is a plus but not required.

Application:
To apply, please submit a cover letter, a current CV with a publication list to Dr. Teng via email: yong.teng@emory.edu

How to Become a Member of ACACR 如何成为ACACR 协会会员

感谢大家对ACACR 的关心和鼓励，更感谢许多志愿者们的付出。我们的财务李勇已把协会的银行帐户，PayPal 帐户开好；我们 IT 小组的戴木水已经将网上自动付款体系建成。下面是如何成为我们协会成员了。

我们有两种会员制，普通会员（regular member) 和 临时会员（associate member)。普通会员又分终生会员（lifetime membership) 以及年度会员， 前者会费 $500, 后者会费每两年$100。临时会员暂不收费，但以后可能会有所改变。

目前我们还是半自动化注册（即有部分是手工）。请到我们网站 acacr.org 在"membership"栏下载注册表，填好后电邮给表最后的邮件地址。

我们共有三种付会员费的方式：

1. 在我们网站上用Paypal(或信用产卡）付tacacr@outlook.com
2. 银行直接Transfer Money (Zelle, like Chase Quickpay) to tacacr@outlook.com.
3. 支票. 请写明付给 "Association of Chinese Americans in Cancer Research, Inc." 需要邮寄支票的，请与Dr. Yong Li 联系，Yong.Li@bcm.edu，请在电邮上注明 ACACR member.

我们将在收到付款后五-七个工作日发出收据。

协会会员的益处：

协会普通会员和临时会员都可以参加WeChat 的讨论，信息交流，年会以及其他一些由ACACR 组织的活动。普通会员还有以下一些额外的福利。

（1）协会内部选举和被选举权；

（2）由ACACR 推荐去AACR 各种委员会和杂志编辑部；

(3）在我们协会网站上招人广告栏上发广告（微信群里的帖子会很快被淹没）；

（4）在我们协会网站上贴一些会议通知；

（5）在我们协会每月一次的 Newsletter 上登广告（非会员收费 $20);

（6）我们协会网站和 Newsletter "Research Highlights" 栏目中将优先选发协会会员刚发表的文章；

（7）今后ACACR 有小型奖励机会（award opportunity), 将优先考虑我们的普通会员；

(8) 今后购买ACACR 赞助商的物品时可能有折扣机会。

普通会员今后可能有的福利还包括会员学术交流活动（annual retreat), 成员互助等。

Association of Chinese Americans in Cancer Research

SCAN me to join the ACACR

Volume 2, Issue 8 February 2022

ASSOCIATOIN OF CHINESE AMERICANS IN CANCER RESEARCH

PO Box 1382,
Timonium, MD 21093

Phone: (443) 923-9498
Email: acacr@weebly.com

We are on the web
http://www.acacr.org/

Our Missions

Our mission is to prevent and cure cancer through fostering interactions and collaborations among Chinese Americans in all areas of cancer research including cancer biology, etiology, genetics, epidemiology, prevention, diagnosis, and treatment. ACACR also promotes interactions and collaborations among professionals of Chinese background and/or ethnicity in cancer research through the exchange of information in education, technology, employment, and business opportunities.

Wish You a Happy and Prosperous Year of Tiger!

Source: www.tusij.com

Management team (web link)

Board of Directors
Shiyuan Cheng, PhD
Wei Gu, PhD
Yibin Kang, PhD
Jinsong Liu, MD, MA, PhD
Hua Lu, MD, PhD
Shaomeng Wang, PhD

President
Lin Zhang, PhD

President Elect
Gloria Su, PhD

General Secretary
Erxi Wu, PhD

Treasurer
Yong Li, PhD

Committee chair/co-chair

Annual meeting
Gensheng Feng, PhD
Tongchuan He, MD, PhD
Binhua Zhou, MD, PhD

Audit
Zhaohui Feng, PhD

Fundraising
Bin Li, MD
Xing Fan, MD PhD

IT-support
Wenwei Hu, PhD
Mushui Dai, MD, PhD

Membership
Yaguang Xi, MD, PhD, MBA

Newsletters
Lanjing Zhang, MD
Shuhang Wang, MD

Past Presidents
2019-2021
Zhenkun Lou, PhD

2017-2018
Shiyuan Cheng, PhD

Call for submissions and volunteers

We would love to hear from you. Any suggestions or ideas are welcome. We also would like to invite you to join our newsletter team. If interested, please email lanjing.zhang@rutgers.edu

SCAN ME

To join the ACACR annual meeting